Pfizer is a global biopharmaceutical company that develops and manufactures innovative medicines and vaccines to improve health outcomes for people around the world. Renowned for its extensive research and development efforts, Pfizer focuses on various therapeutic areas including vaccines, oncology, immunology, cardiology, endocrinology, and rare diseases. The company is committed to addressing significant health challenges through the discovery of new treatments, leveraging cutting-edge science and technology. Pfizer also emphasizes partnerships and collaborations to expand its capabilities and enhance access to healthcare solutions. Read More
Nvidia CEO Jensen Huang cautioned Elon Musk against underestimating the challenges of semiconductor manufacturing, saying building a chip fab like TSMC's is "extremely hard."
The financial markets are increasingly flashing warning signs that an economic recession may be on the horizon, prompting investors to re-evaluate their strategies. A confluence of indicators, from inverted yield curves to softening corporate earnings and shifting consumer sentiment, suggests that the robust growth seen in recent years could be
Explore the S&P500 index on Friday and find out which stocks are the most active in today's session. Stay updated with the stocks that are capturing market interest and driving market movements.
New York, NY – November 7, 2025 – The U.S. stock market has been gripped by a significant downturn in early November 2025, culminating in a brutal week that saw the Nasdaq Composite, S&P 500, and Dow Jones Industrial Average all close sharply lower. This market correction is primarily fueled
The U.S. stock market experienced a notable downturn today, November 6, 2025, as investors grappled with growing apprehension over the lofty valuations of artificial intelligence (AI) stocks and a significantly deteriorating job market. Major indices, including the S&P 500, Nasdaq Composite, and Dow Jones Industrial Average, registered sharp
Value stocks typically trade at discounts to the broader market, offering patient investors the opportunity to buy businesses when they’re out of favor.
The key risk, however, is that these stocks are usually cheap for a reason – five cents for a piece of fruit may seem like a great deal until you find out it’s rotten.
A groundbreaking $2 million grant from the National Institutes of Health (NIH) is set to dramatically accelerate advancements in gene-editing technology, with artificial intelligence (AI) emerging as the linchpin in the quest to develop cures for a myriad of debilitating diseases. This significant investment is poised to revolutionize how scientists approach genetic disorders, moving beyond [...]
Stay informed about the most active S&P500 stocks in today's session as we take a closer look at what's happening on the US markets on Thursday. Discover the stocks that are generating the highest trading volume and driving market activity.
San Diego, CA – November 6, 2025 – Ligand Pharmaceuticals (NASDAQ: LGND) has recently captured the financial spotlight, with its stock hitting a remarkable 52-week high of $197.78 on November 6, 2025. This significant milestone comes on the heels of a robust third-quarter 2025 earnings report that dramatically exceeded analyst expectations,
As November 2025 unfolds, the global stock markets find themselves at a critical juncture, struggling to reclaim the robust bullish momentum that characterized much of the preceding years. A palpable shift in investor sentiment is emerging, with an increasing number of market participants questioning the lofty valuations, particularly within the
Medication company Viatris (NASDAQ:VTRS) beat Wall Street’s revenue expectations in Q3 CY2025, but sales were flat year on year at $3.76 billion. The company’s full-year revenue guidance of $14.1 billion at the midpoint came in 1.2% above analysts’ estimates. Its non-GAAP profit of $0.67 per share was 8.5% above analysts’ consensus estimates.
Delaware Chancery Judge Morgan Zurn ruled that Pfizer’s objections did not justify delaying Novo’s $10 billion acquisition of obesity-drug startup Metsera.
